In another study from the Czech Republic that included 74 IBD patients who switched to biosimilar infliximab and 119 biologic-naive patients, remission rates at week 0 and 56 were similar at 72.2% and 77.8% and no difference in CRP or fecal calprotectin (FC) was noted at 56 weeks.23 There was no increase in immunogenicity in patients switched from originator to biosimilar infliximab. This evidence concerns the gene CRP and inflammatory bowel disease.